187 related articles for article (PubMed ID: 35524036)
1. Semaglutide in routine clinical practice: interesting news from real-world evidence.
Formoso G; Baroni MG
J Endocrinol Invest; 2022 Aug; 45(8):1599-1600. PubMed ID: 35524036
[No Abstract] [Full Text] [Related]
2. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
Scheen AJ
Lancet Diabetes Endocrinol; 2020 May; 8(5):350-352. PubMed ID: 32333865
[No Abstract] [Full Text] [Related]
3. Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
Kalra S; Kalhan A; Berard L
Postgrad Med; 2020 Nov; 132(8):663-666. PubMed ID: 32781867
[No Abstract] [Full Text] [Related]
4. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
5. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
6. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials.
Mellbin LG; Bhatt DL; David JP; Ekström K; Petrie MC; Rasmussen S; Vilsbøll T
Eur Heart J; 2024 Apr; 45(15):1371-1374. PubMed ID: 38416593
[No Abstract] [Full Text] [Related]
8. Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice.
Karásek D
Vnitr Lek; 2022; 68(2):89-95. PubMed ID: 36208922
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
10. [The glucagon-like peptide-1 receptor-agonist semaglutide].
Boje AD; Juhl CR; Torekov SS; Madsbad S
Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
[TBL] [Abstract][Full Text] [Related]
11. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.
Rajamand Ekberg N; Bodholdt U; Catarig AM; Catrina SB; Grau K; Holmberg CN; Klanger B; Knudsen ST
Prim Care Diabetes; 2021 Oct; 15(5):871-878. PubMed ID: 34183269
[TBL] [Abstract][Full Text] [Related]
12. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
13. Add-on value of tirzepatide versus semaglutide.
Scheen AJ
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):377-378. PubMed ID: 35468323
[No Abstract] [Full Text] [Related]
14. Semaglutide for Weight Loss: Was It Worth the Weight?: Erratum.
Cardiol Rev; 2023 Jan-Feb 01; 31(1):57. PubMed ID: 36469361
[No Abstract] [Full Text] [Related]
15. Oral semaglutide (Rybelsus) for type 2 diabetes.
Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
[No Abstract] [Full Text] [Related]
16. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
17. Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
Doggrell SA
Expert Opin Biol Ther; 2020 May; 20(5):489-492. PubMed ID: 32005073
[No Abstract] [Full Text] [Related]
18. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
Semenya AM; Wilson SA
Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
[No Abstract] [Full Text] [Related]
19. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.
Hedrington MS; Tsiskarishvili A; Davis SN
Expert Opin Biol Ther; 2018 Mar; 18(3):343-351. PubMed ID: 29431519
[TBL] [Abstract][Full Text] [Related]
20. In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes.
Med Lett Drugs Ther; 2022 May; 64(1650):79. PubMed ID: 35536124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
